Search

VENTANA PD-L1 (SP263) Assay (FDA Approved)

Predictive IHC assay

PD-L1 SP263 Assay UC stain image

Guiding immunotherapy decisions

VENTANA PD-L1 (SP263) Assay identifies patients who are most likely to respond to specific therapy, so that you can make informed, efficient treatment decisions that can lead to better clinical outcomes and improved quality of life. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.

CDx-slide-vials-pill-RxDx.png
Do you have any questions?
CONTACT US
Empowering pathologists to answer PD-L1 questions
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying:

 

  • Non-small cell carcinoma (NSCLC) patients eligible for treatment with TECENTRIQ® (atezolizumab)
  • NSCLC patients eligible for treatment with LIBTAYO® (cemiplimab)
VENTANA PD-L1 (SP263) Assay further benefits patients by:

 

  • Providing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)†
  • Allowing optimal lung tissue management through PD-L1 testing of archived unstained slides within 12 months

Related information

Woman at desk

Reagent and ancillary product information

Search for product information for reagents, ancillaries and bulks.

VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemistry assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the programmed death ligand-1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue specimens by light microscopy. The VENTANA PD-L1 (SP263) Assay is used with the OptiView DAB IHC Detection Kit for staining on the BenchMark ULTRA instrument.

NSCLC:

PD-L1 expression in tumor cell (TC) membrane as detected by VENTANA PD-L1 (SP263) Assay in NSCLC is indicated as an aid in identifying patients for treatment with TECENTRIQ® (atezolizumab).

PD-L1 expression in tumor cell (TC) membrane as detected by VENTANA PD-L1 (SP263) Assay in NSCLC is indicated as an aid in identifying patients for treatment with LIBTAYO® (cemiplimab).

Table 1. Therapy and associated indication.

View Full Table
close

Table 1. Therapy and associated indication.

Indication for use Therapy PD-L1 Expression
NSCLC TECENTRIQ® ≥1 % TC
LIBTAYO® ≥50 % TC
*Please refer to the VENTANA PD-L1 (SP263) Assay method sheet for the full intended use statement and approved therapeutic labeling.

You might be interested in

...
    ...
    †IC staining with this assay is not used to assess PD-L1 status in NSCLC.
    VENTANA anti-ALK (D5F3), lung carcinoma
    VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (CE IVD)
    VENTANA ALK (D5F3) CDx Assay (PMA)
    VENTANA ALK (D5F3) CDx Assay (US FDA Approved)
    VENTANA HER2 Dual ISH DNA Probe Cocktail Assay CDx icon
    VENTANA HER2 Dual ISH DNA Probe Cocktail assay (CE IVD)
    cobas® 4800 BRAD V600 Mutation Test
    cobas® 4800 BRAF V600 Mutation Test
    product box for cobas EZH2
    cobas® EZH2 Mutation Test
    VENTANA PD-L1 (SP263) Assay, non-small cell lung cancer (NSCLC), urothelial carcinoma, bladder cancer
    VENTANA PD-L1 (SP263) Assay (CE IVD)
    HER2 DUAL ISH thumbnail image
    VENTANA HER2 Dual ISH DNA Probe Cocktail assay (US FDA Approved)
    Roche VENTANA HER2 4B5 breast cancer IHC stain
    VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (CE IVD)
    VENTANA MMR RxDx panel icon
    VENTANA MMR RxDx Panel (CE IVD)
    VENTANA MMR RxDx panel icon
    VENTANA MMR RxDx Panel (US FDA Approved)
    Roche Pathway HER2 4B5 assay slide and therapy image
    PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody
    VENTANA FOLR1 (FOLR-2.1) RxDx Assay (US FDA Approved)
    VENTANA FOLR1 (FOLR1-2.1) RxDx Assay
    VENTANA PD-L1 SP142 Assay
    VENTANA PD-L1 (SP142) Assay (US FDA Approved)
    PD-L1 SP142 Assay
    VENTANA PD-L1 (SP142) Assay (CE IVD)